Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Vanda Pharmaceuticals Inc. (VNDA : NSDQ)

• Company Description    Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. It is developing important new medicines to improve the lives of patients. It uses new technologies, including genetics & genomics, to inform our drug discovery, our clinical trials, and our commercial positioning of our compounds. The Company has three product candidates in clinical development. It's lead product candidate, iloperidone, is a compound for the treatment of schizophrenia & bipolar disorder & is in a Phase III clinical trial for schizophrenia. It's second product candidate, is a compound for the treatment of insomnia & depression which is currently in a Phase III clinical trial for insomnia. It's third product candidate, is a compound for the treatment of excessive sleepiness & is ready for a Phase II clinical trial. Number of Employees: 203

• Price / Volume Information    Yesterday's Closing Price: $4.86 Daily Weekly Monthly 20 Day Moving Average: 347,436 shares Shares Outstanding: 58.93 (millions) Market Capitalization: $286.42 (millions) Beta: 0.68 52 Week High: $6.37 52 Week Low: $3.81 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 4.29% 1.16% 12 Week 11.21% -3.59% Year To Date 1.46% -4.14%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2200 PENNSYLVANIA AVENUE NW SUITE 300E - WASHINGTON,DC 20037 USA ph: 202-734-3400 fax: 202-296-1450 pr@vandapharma.com http://www.vandapharma.com

• General Corporate Information    Officers Mihael H. Polymeropoulos - Chief Executive Officer; Chairman and President Kevin Moran - Chief Financial Officer Richard W. Dugan - Director Anne Sempowski Ward - Director Phaedra Chrousos - Director Peer Information Vanda Pharmaceuticals Inc. (CORR.) Vanda Pharmaceuticals Inc. (RSPI) Vanda Pharmaceuticals Inc. (CGXP) Vanda Pharmaceuticals Inc. (BGEN) Vanda Pharmaceuticals Inc. (GTBP) Vanda Pharmaceuticals Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 921659108 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 07/30/25 Share - Related Items Shares Outstanding: 58.93 Most Recent Split Date: (:1) Beta: 0.68 Market Capitalization: $286.42 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.31 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.49 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 07/30/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.56 Price/Cash Flow: - Price / Sales: 1.42 EPS Growth vs. Year Ago Period: -614.29% vs. Previous Quarter: -525.00% Sales Growth vs. Year Ago Period: 5.43% vs. Previous Quarter: -5.91% ROE 06/30/25 - - 03/31/25 - -8.30 12/31/24 - -3.49 ROA 06/30/25 - - 03/31/25 - -6.85 12/31/24 - -2.90 Current Ratio 06/30/25 - - 03/31/25 - 3.93 12/31/24 - 4.39 Quick Ratio 06/30/25 - - 03/31/25 - 3.91 12/31/24 - 4.37 Operating Margin 06/30/25 - - 03/31/25 - -21.98 12/31/24 - -9.51 Net Margin 06/30/25 - - 03/31/25 - -21.98 12/31/24 - -9.51 Pre-Tax Margin 06/30/25 - - 03/31/25 - -27.63 12/31/24 - -11.53 Book Value 06/30/25 - - 03/31/25 - 8.68 12/31/24 - 9.24 Inventory Turnover 06/30/25 - - 03/31/25 - 6.77 12/31/24 - 7.17 Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©